A coronary sinus reducer, a small hourglass-shaped device implanted near the heart, has demonstrated significant benefits for patients with refractory angina, according to research presented in a recent study. The condition affects an estimated 300,000 people in England and involves chest pain that persists despite standard medical interventions including medications, stents, and bypass surgery.
The study, described as the largest of its kind globally, analyzed data from 491 patients with refractory angina between 2014 and 2024, with 474 receiving the implant at 19 hospitals across England and Scotland. Researchers found that the device produced a substantial reduction in chest pain symptoms in 75% of patients within six months of implantation. The procedure is performed using minimally invasive keyhole surgery through the patient’s neck, with most patients discharged either on the day of the procedure or the following day. Serious complications were rare among those studied.
The implant works by narrowing a vein at the back of the heart to redirect blood flow toward areas of the heart muscle receiving insufficient oxygen. Each device costs the NHS £11,400. Despite these findings, the implant remains an experimental treatment, with only a small fraction of the estimated 300,000 people with refractory angina having received one to date.
Cardiac specialists note that the device can substantially improve quality of life and mental wellbeing for patients with this debilitating condition. However, additional trials are required and NHS funding approval is necessary before the coronary sinus reducer can be considered standard treatment. Clinical experts have described the results as reassuring and indicated that the device offers meaningful hope for individuals living with refractory angina.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI